Sign in Subscribe
Drug approval

FDA Approves Long-Lasting HIV Prevention Drug Lenacapavir

Strategic Insights

— 1 min read

The US Food and Drug Administration (FDA) has approved lenacapavir, a groundbreaking, injectable HIV prevention drug that offers long-lasting protection against HIV infection. Administered once every six months, this game-changing treatment expands prevention options for individuals at risk of HIV infection, particularly those who struggle with daily pill regimens. Unlike daily PrEP pills, lenacapavir attacks HIV's protective shell, preventing the virus from copying itself at multiple stages.

Key Takeaways:

  • Lenacapavir is a long-acting HIV prevention drug that offers protection for six months with a single injection under the skin.
  • The drug is highly effective, but it does not protect against other sexually transmitted infections, emphasizing the importance of using condoms and regular screening.
  • The most common side effects of lenacapavir are mild discomfort at the injection site, which usually resolves quickly on its own, and nausea, which is uncommon.
  • Lenacapavir can interact with some other medicines, and its use must be supervised by medical professionals.
  • The price of lenacapavir will be a significant factor in its global rollout, with estimated costs varying by country.
  • Researchers estimate that generic manufacturers could produce the drug for as little as $25 a year in low- and middle-income countries.
  • A once-yearly version of lenacapavir has been presented by Gilead, the pharmaceutical company behind the treatment, offering the possibility of even longer protection in the future.
  • Lenacapavir is a major step forward in HIV prevention, providing a simple and highly effective option for individuals who find daily pills difficult to administer.

Statistics:

  • The FDA approval of lenacapavir marks a significant advancement in HIV prevention, offering long-lasting protection against HIV infection.
  • Lenacapavir is priced at around $28,000 per year in the United States, with costs differing in other countries.
  • The drug can protect individuals for six months with a single injection, making it a convenient option for those who struggle with daily pill regimens.
  • The most common side effects of lenacapavir are mild discomfort at the injection site and nausea.
  • Researchers estimate that the cost of producing lenacapavir for low- and middle-income countries could be as little as $25 a year.

Sources:

  • Gilead
  • US Food and Drug Administration
  • National Institute for Health and Care Excellence (UK)

Read more